2018 ANNUAL REPORT

PARTNERSHIP FOR clean competition

1 Olympic Plaza Colorado Springs, CO, 80909

cleancompetition.org

ABOUT The PCC



Doping is a global problem. We fund solutions.

THE PARTNERSHIP FOR CLEAN COMPETITION IS A NONPROFIT, 501(C)(3) ORGANIZATION WORKING TO PROTECT THE INTEGRITY OF SPORT AND PUBLIC HEALTH BY ENGAGING AND SUPPORTING THE WORLD'S TOP SCIENTISTS AND INNOVATORS IN HIGH-QUALITY ANTI-DOPING RESEARCH AND DEVELOPMENT.

PROTECTING ATHLETES THROUGH A COMMITMENT TO FUNDING HIGH QUALITY ANTI-DOPING SCIENCE.

Contents

- 04 WHERE ARE WE NOW
- 06 BOARD OF GOVERNORS
- 07 STAFF AND 17 OFFICERS

- 08 SCIENTIFIC ADVISORY BOARD
- 11 A YEAR IN REVIEW
- 17 FINANCIAL OVERVIEW



WHERE WE ARE NOW

A letter from Executive Director Michael Pearlmutter

2018 was a milestone year for the researchers we support and the athletes their work protects.

Since the first grant was funded back in 2008, the PCC has been on the front lines of the anti-doping fight – a fight which has helped shape the organization itself. As doping methods and substances grow increasingly complex, the PCC has responded with agile programming thoughtfully developed to address our stakeholders', and the entire anti-doping community's, challenges.

At the core of a successful 2018 were the actions we took to expand and evolve programming, building upon our 2017 priorities. A redesigned Fellowship program, which allows candidates to perform studies at their host institution, resulted in the funding of four new Fellows in Australia, Denmark, the UK, and the US. This is a substantial increase over the two Fellows we funded in total from 2014 through 2017. The NHL renewed their commitment to the PCC and we acquired a new Contributor: Comprehensive Drug Testing (CDT). We would like to thank both organizations for their commitment to supporting innovative science and sporting integrity.

Science is still our most distinguishing work. While there are too many projects to highlight in this letter, here are just a few from 2018. An improved method for detecting growth hormone was implemented in WADA-Accredited labs around the world in 2018, a direct result of the PCC's IGF-1 Working Group. This will provide a robust and consistent method to detect a pervasive threat to clean athletes. Our Translational Research Fund (TRF) facilitated three new prototypes for the PCC's steroidome project through a collaboration with Activated Research Company and researchers at the University of Texas, bringing us closer to more sensitive detection of steroid misuse in sport. The TRF also supported the first PCC field trials, designed to assess the viability of alternative matrices for in-competition testing. With the help of Major League Baseball and CDT, the trials were a great success and demonstrated oral fluids and exhaled breath as pragmatic complements to urine and blood testing. Finally, and perhaps most importantly, we were able to support scientists globally with more than \$3.8 M in awards, a 56% increase over 2017. The funding was dispersed to researchers in 11 countries and we can't wait to see the results of their important work.

> We would like to thank all of our dedicated stakeholders for supporting the PCC over the past ten years, especially our Founding Members and Contributors, dedicated Board Members, and the research scientists carrying out the work that brings us all together. Through the collaboration and investment of our engaged community of clean sport champions, the PCC is confident we can continue on our growth trajectory.

LEADERSHIP

Board of Governors



Dan Halem

MAJOR LEAGUE BASEBALL

Board Chair*

Major League Baseball's Deputy Commissioner, Baseball Administration and Chief Legal Officer, Mr. Halem oversees all collective bargaining issues with the MLB Players Association, including the annual updates to Joint Drug Prevention and Treatment Program. Mr. Halem also works closely with club management officials and helps directs the administration of MLB's revenue sharing system, the debt-service rule, the competitive balance tax, the salary arbitration system, and the amateur draft support program. Prior to joining MLB, Mr. Halem was a partner at the law firm of Proskauer Rose, where he represented and counseled the NBA, the WNBA, the NHL, and the New York Jets of the NFL. Mr. Halem graduated from Cornell University's School of Industrial and Labor Relations in 1988 and from Harvard Law School, magna cum laude, in 1991.



Chris McCleary

UNITED STATES OLYMPIC & PARALYMPIC COMMITTEE

In his current role as the general counsel for the United States Olympic and Paralympic Committee, Mr. McCleary is responsible for all legal issues faced by the organization and all necessary functions as corporate secretary for the USOPC Board of Directors. Additionally, he serves as the organization's ethics officer, coordinating with the USOPC Ethics Committee, and oversees the USOPC's partnerships with the World Anti-Doping Agency, U.S. Anti-Doping Agency, and Partnership for Clean Competition. McCleary joined the USOPC from Visa Inc., where he served eight years as the senior vice president and senior associate general counsel of global brand and client management, in which he led the company's worldwide legal operations in marketing, sponsorships, intellectual property, and client licensing.



Travis Tygart

UNITED STATES ANTI-DOPING AGENCY

Serving as USADA's Chief **Executive Officer since** September 2007, Travis T. Tygart leads the organization's efforts to preserve the integrity of competition, inspire true sport, and protect the rights of clean athletes. Under Tygart's leadership, some of USADA's most significant efforts to protect athletes' rights have come in the form of international advocacy of clean sport, most recently in relation to the Russian doping scandal, and in the form of major investigations. Working alongside federal authorities, USADA investigated the international steroid bust, Operation Raw Deal, and the international doping conspiracy involving the BALCO laboratory in San Francisco. Tygart also led the investigation into the U.S. Postal Service pro-cycling team doping conspiracy and spearheaded the publication of the Reasoned Decision in the Lance Armstrong case.



Adolpho Birch III

NATIONAL FOOTBALL LEAGUE

Senior Vice President of Labor Policy & League Affairs for the National Football League, Birch oversees the development, administration and enforcement of the League's critical policies respecting the integrity of the game, including those on substances of abuse, performance-enhancing drugs, gambling and criminal misconduct. Mr. Birch also has advanced the League's legislative and political interests, working with federal, state and local officials on key league issues such as youth concussion laws, the League's tax status and the FCC's blackout rule. Prior to joining the NFL, Mr. Birch was in private practice in Houston, Texas, Mr. Birch attended Vanderbilt University Law School as a Patricia Roberts Harris Scholar.

Staff & Officers







Michael Pearlmutter EXECUTIVE DIRECTOR

Jenna Celmer STAKEHOLDER ENGAGEMENT MANAGER

Kevin Manara NATIONAL FOOTBALL LEAGUE

Kevin Manara serves as Senior Labor

Relations Counsel for the NFL. His

Michael Pearlmutter was named Executive Director for the Partnership for Clean Competition Research Collaborative in January 2014. In this role, Pearlmutter is responsible for developing, directing, and driving organizational strategy and overseeing daily operations, including managing the organization's \$4M budget,fundraising, business development, grant administration, scientific outreach, and communication with the PCC Board of Governors and Scientific Advisory Board. Ms. Celmer joined the PCC as Stakeholder Engagement Manager in March of 2016 to provide dedicated outreach and communications services to the PCC's numerous sponsors, researchers, and collaborators. In this role, Celmer supports the promotion, growth and advancement of PCC programming and partnerships through implementing strategic engagement initiatives, creative marketing efforts, and mission-driven support mechanisms for the anti-doping community.

responsibilities include the administration of the League's collective bargaining agreement with its players, as well as enforcement of the League's policies on performanceenhancing substances, personal conduct and substances of abuse. Kevin represents NFL clubs in grievances filed by players under the CBA, prosecutes appeals of discipline imposed under League policies and advises clubs on a variety of contractual, disciplinary and other labor-related matters. Kevin was a member of the NFL Management Council's bargaining team during negotiations that resulted in the 2011 CBA and the 2014 drug and steroid policies. Prior to joining the NFL, Kevin was an associate in the Labor & Employment department at Proskauer Rose. Kevin graduated from Johns Hopkins University, where he played varsity football, and earned his law degree with honors from New York Law School.

Scientific Advisory Board





LARRY BOWERS, PH.D.

As USADA'S Chief Science Officer from 2000 to 2016, Dr. Bowers provided leadership and scientific support for USADA's research sample collection planning, results management, arbitration, education programs, and the prestigious USADA Annual Symposium. Past Associate Editor (Drug Testing and Toxicology) for the journal, Clinical Chemistry, Dr. Bowers was the deputy director of the Athletic Drug Testing Laboratory for the 1996 Olympic Games, and has served on several scientific organizations Board of Directors. Dr. Bowers is currently a member of the World Anti-Doping Agency (WADA) Laboratory Accreditation Working Group.

GARY GREEN, M.D.

Gary Green, MD, was appointed Medical Director for Major League Baseball in 2010. He also serves as research director for MLB. He is a fellow in the American College of Physicians and American College of Sports Medicine and a Clinical Professor in the UCLA School of Medicine in the Division of Sports Medicine, Dr. Green is the head team physician for Pepperdine University and serves on the California Interscholastic Federation Medical Advisory Committee. He is also on review boards for USADA for adverse analytical findings and therapeutic use exemptions.





ANNETTE SALMEEN, D.PHIL.

Dr. Salmeen, D.Phil., was a 1996 Olympian and gold medalist. She served as an athlete's representative for the USA Swimming national governing body from 1996 to 2005. In 2005, she was elected as an athlete member of the U.S. Anti-Doping Agency Board of Directors and served until 2012. She was a member of the USADA board research committee and was also involved with efforts to support athlete education and the USADA True Sport initiative. She earned her doctoral degree in Biochemistry as a Rhodes Scholar at Oxford in 2001 and studied growth factor signalling pathways as a post-doctoral fellow in the Chemical and Systems Biology department at Stanford. She is currently a lecturer in the Human Biology Program at Stanford.

GERHARD BAUMANN, M.D.

Past Chief of Endocrinology and Metabolism at the Veterans Administration Lakeside Medical Center and the Associate Director of the Northwestern University General Clinical Research Center, Dr. Baumann is a Professor of Medicine Emeritus at Northwestern University. Dr. Baumann discovered the growth hormone binding protein, the circulating ectodomain, of the growth hormone receptor.

Scientific Advisory Board





LAWRENCE SILVERMAN, PH.D.

Emeritus Professor of Pathology at the University of Virginia, Dr. Silverman also served as Director of the Molecular Diagnostics, Clinical Genomics, and Immunology Laboratories at the University of Virginia, as well as Director of the Division of Molecular Pathology, and Director of the Immunochemistry/Molecular Genetics Laboratory at the University of North Carolina Hospitals. Dr. Silverman is a diplomate of the American Board of Clinical Chemistry and a Fellow of the American College of Medical Genetics.

JOHN YATES III, PH.D.

The Ernest W. Hahn Professor in the Department of Chemical Physiology and Molecular & Cellular Neurobiology at The Scripps Research Institute, Dr. Yates is the lead inventor of the SEQUEST software for correlating tandem mass spectrometry data to sequences in the database and developer of the shotgun proteomics technique for analysis of protein mixtures. Dr. Yates was ranked by Citation Impact, Science Watch as one of the Top 100 Chemists for the decade, 2000-2010. Dr. Yates is the Editor in Chief at the Journal of Proteome Research.



MICHAEL M. SAWKA, PH.D.

Chief Scientific Officer of Environmental Physiology and Hydration Associates, Adjunct Professor of Biological Sciences at Georgia Institute of Technology and past Chief of Thermal and Mountain Medicine at the US Army Research Institute of Environmental Medicine, Dr. Sawka is an expert in environmental physiology (heat, cold, highaltitude), blood volume control, fluid/ electrolyte balance, temperature regulation, and exercise physiology.



ALVIN M. MATSUMOTO, M.D.

Dr. Matsumoto is a Professor of Medicine in the Division of Gerontology & Geriatric Medicine at the University of Washington, School of Medicine in Seattle. He is Director of the Clinical Research Unit, Associate Director of the Geriatric Research, Education & Clinical Center, Acting Chief of the Gerontology Section and an Attending Physician in Internal Medicine, Geriatric Medicine and Endocrinology & Metabolism at the Department of Veterans Affairs Puget Sound Health Care System. He is Chair of the Laureate Awards Committee of The Endocrine Society, Co-Chair of the Partnership for the Accurate Testing of Hormones (PATH), serves as an Editor for the Journal of Clinical Endocrinology & Metabolism and has served on USADA's Research Policy Advisory Committee.

Scientific Advisory Board





STEVE ELLIOT, PH.D.

Recently retired from his Scientific Executive Director Position at Amgen, where he had worked since 1983, Dr. Elliot continues to work in conjunction with the antidoping movement. During his early years at the company, he performed structure-function studies on erythropoietin and the erythropoietin receptor and is the inventor of Aranesp, a re-engineered analog of rHuEpo with a longer serum half-life. His discoveries played a key role in three cross country skiers being stripped of their gold medals and suspended from competition for two years following the 2002 Olympic Winter Games.

MATTHEW FEDORUK, PH.D.

Dr. Fedoruk joined USADA in 2011 as Science Director and is responsible for providing scientific expertise to drive USADA's science, testing, results management, and supplement areas. As a Canadian, he was responsible for science and medical issues during his tenure at the Canadian Centre for Ethics in Sport, Canada's anti-doping agency. As a member of the Organizing Committee for the 2010 Vancouver Olympic and Paralympic Winter Games, he managed anti-doping testing, education, and laboratory analysis challenges before and during the Winter Games. He holds a Ph.D. in Pathology and Laboratory Medicine from the University of British Columbia and is an avid outdoor enthusiast, enjoying the endless sunshine and high-altitude training in Colorado with his family.



JAMES T. DALTON, PH.D.

James T. Dalton, Ph.D. is Dean and Professor of Pharmaceutical Sciences in the College of Pharmacy at the University of Michigan. He received his Bachelor of Science in Pharmacy from the University of Cincinnati (1986) and Doctor of Philosophy in pharmaceutics and pharmaceutical chemistry from Ohio State University (1990). Dean Dalton rose through the faculty ranks in the Department of Pharmaceutical Sciences in the College of Pharmacy at the University of Tennessee (1992-2000) before returning to Ohio State where he served as Professor and Chair in the Division of Pharmaceutics (2000-2007). He began an entrepreneurial leave of absence from Ohio State in 2005 and finally left OSU in 2007 to devote his full time effort as Chief Scientific Officer at GTx, Inc. in Memphis, TN (2007-2014) where he oversaw the preclinical and clinical development of selective androgen receptor modulators.

2018 IN REVIEW

Grants Approved

\$3.8 M USD AWARDED TO SCIENTISTS

Fellowships

- DANIELLE MONCRIEFFE, KING'S COLLEGE LONDON (UK)
- JACOB BEJDER, UNIVERSITY OF COPENHAGEN (DE)
- LAURA GARVICAN-LEWIS, AUSTRIALIAN CATHOLIC UNIVERSITY (AU)
- SCOTT LACOMBE, DELL PEDIATRIC INSTITUTE (US)

TRF Awards

- ACTIVATED RESEARCH COMPANY (US) PROTOTYPE REACTOR PHASE II
- ACTIVATED RESEARCH COMPANY (US) PROTOTYPE REACTOR PHASE III
- CDT (US) BREATH AND ORAL FLUIDS TRIAL COLLECTION
- DR. DANIEL EICHNER, SMRTL (US) BREATH AND ORAL FLUIDS
 TRIAL ANALYSIS
- DR. MARIO THEVIS, SPORT UNIVERSITY COLOGNE (DE) ASSESSING THE STABILITY OF MODEL SUBSTANCES CAPTURED IN EXHALED-BREATH COLLECTION DEVICES AND CROSS-COMPARISON OF FIRST-AND SECOND-GENERATION SENSABUES TEST KITS

Micro-Grants

- DR. GEMMA REVERTER BRANCHAT, IMIM-HOSPITAL DEL MAR (BR) DBS POTENTIAL FOR GH-RELEASING PEPTIDES BY ASSESSMENT IN SUBJECTS HAVING RECEIVED GHRP-2
- DR. JAMES HOPKER, UNIVERSITY OF KENT (UK) DEVELOPMENT OF AN ATHLETE PERFORMANCE PASSPORT FOR ANTI-DOPING IN SPORTS: A PILOT STUDY
- DR. MALCOLM MCLEOD, AUSTRALIAN NATIONAL UNIVERSITY
 (AU) ESSENTIAL REFERENCE MATERIALS TO ADVANCE THE
 LONG TERM DETECTION OF TESTOSTERONE ABUSE
- DR. NIKOLAI NORDSBORG, UNIVERSITY OF COPENHAGEN (DK) DETECTION OF RECOMBINANT HUMAN ERYTHROPOIETIN USING FLOW-CYTOMETRY
- DR. OLE JENSEN, UNIVERSITY OF SOUTHERN DENMARK
 (DK) PRECISION PROFILING OF EPO GLYCOSYLATION
- DR. ROBERT GIESE, NORTHEASTERN UNIVERSITY (US) BREATH TEST FOR PROFILING DRUGS OF ABUSE
- DR. DILSHADBEK USMANOV TURSUNBAEVICH, UZBEKISTAN ANTI-DOPING LABORATORY (UK) DEVELOPMENT OF SURFACE IONIZATION METHOD FOR HIGH SENSITIVE DETECTION OF MORPHINE IN BIOFLUIDS

IGF-1 Working Group

- DR. ANDY HOOFNAGLE, UNIVERSITY OF WASHINGTON (US)
- DR. ANTHONY BUTCH, UCLA (US)
- DR. DANIEL EICHNER, SMRTL (US)
- DR. DAVID COWAN, KING'S COLLEGE LONDON (UK)
- DR. MARIO THEVIS, SPORT UNIVERSITY COLOGNE (DE)

Grants

- DR. ALEXANDRE MARCHAND, AFLD (FR) DETECTION CAPACITY OF EPO BIOSIMILARS WITH LOW MOLECULAR WEIGHT AFTER IN VIVO ADMINISTRATION
- DR. CARSTEN LUNDBY, RIGSHOSPITALET (DK) APPLYING THE OPCO BLOOD VOLUME ANALYSER TO ANTI-DOPING SETTINGS RESUBMISSION
- DR. CHRISTOPH BORCHERS, MCGILL UNIVERSITY (CA)
 LONGITUDINAL BLOOD PROTEOME QUANTIFICATION
 USING DBS-MRM-MS TO SCREEN FOR BLOOD DOPING
 PRACTICES
- DR. CHRISTOPHE STOVE, UNIVERSITY OF GHENT (BE) SENSING THE BIO-SENSOR – BIOASSAY-BASED SCREENING AS A NEW CONCEPT TO SCREEN FOR HIF STABILIZERS
- DR. DAVID HANDELSMAN, ANZAC RESEARCH INSTITUTE (AU) DETECTION OF TESTOSTERONE MICRODOSING IN WOMEN RESUBMISSION
- DR. HERB TOBIAS, DELL PEDIATRIC INSTITUTE (US) ARC CATALYTIC COMBUSTION REACTORS FOR FAST GCC-IRMS AND GC×GCC-IRMS OF URINARY STEROIDS
- DR. MARIKE GRAU, SPORT UNIVERSITY COLOGNE (DE)
 POTENTIAL OF RBC DEFORMABILITY AS NEW MARKER
 TO DETECT AUTOLOGOUS BLOOD DOPING
- DR. MARIO THEVIS, SPORT UNIVERSITY COLOGNE (DE) DEVELOPMENT OF AN INTERNAL STANDARD FOR ROUTINE DOPING CONTROL ERYTHROPOIETIN ANALYSIS
- DR. MICHAEL POLET, UNIVERSITY OF GHENT (BE)
 COMPREHENSIVE DETECTION OF DOPING AGENTS BY
 LOW ENERGY EI GCQTOF RESUBMISSION
- DR. NICOLAS LEUENBERGER, SWISS ANTI-DOPING LABORATORY (CH) CIRCULAR AND LINER ALAS2 RNA IN DRIED BLOOD SPOTS AS POTENTIAL BIOMARKER OF BLOOD DOPING

Publications

COX, HOLLY D., ET AL. "EVALUATION OF SERUM MARKERS FOR IMPROVED DETECTION OF AUTOLOGOUS BLOOD TRANSFUSIONS." HAEMATOLOGICA, VOL. 103, NO. 10, OCT. 2018, PP. E443-45. DOI.ORG (CROSSREF), DOI:10.3324/HAEMATOL.2018.190918.

DAVIES, STEPHEN R., ET AL. "PRODUCTION OF CERTIFIED REFERENCE MATERIALS FOR THE SPORTS DOPING CONTROL OF THE REV-ERB AGONIST SR9009." DRUG TESTING AND ANALYSIS, VOL. 11, NO. 2, FEB. 2019, PP. 257-66. DOI.ORG (CROSSREF), DOI:10.1002/DTA.2485.

DESHARNAIS, PHILIPPE, ET AL. "DETECTION OF ERYTHROPOIESIS STIMULATING AGENTS IN URINE SAMPLES USING A CAPILLARY WESTERN SYSTEM." DRUG TESTING AND ANALYSIS, VOL. 10, NO. 11-12, NOV. 2018, PP. 1698-707. DOI.ORG (CROSSREF), DOI:10.1002/DTA.2528.

GARVICAN-LEWIS, LAURA A., VICTOR L. VUONG, ANDREW D. GOVUS, YORCK OLAF SCHUMACHER, ET AL. "INFLUENCE OF COMBINED IRON SUPPLEMENTATION AND SIMULATED HYPOXIA ON THE HAEMATOLOGICAL MODULE OF THE ATHLETE BIOLOGICAL PASSPORT." DRUG TESTING AND ANALYSIS, VOL. 10, NO. 4, APR. 2018, PP. 731-41. DOI.ORG (CROSSREF), DOI:10.1002/DTA.2303.

GARVICAN-LEWIS, LAURA A., VICTOR L. VUONG, ANDREW D. GOVUS, PETER PEELING, ET AL. "INTRAVENOUS IRON DOES NOT AUGMENT THE HEMOGLOBIN MASS RESPONSE TO SIMULATED HYPOXIA." MEDICINE & SCIENCE IN SPORTS & EXERCISE, VOL. 50, NO. 8, AUG. 2018, PP. 1669-78. DOI.ORG (CROSSREF), DOI:10.1249/MSS.000000000001608.

HASSANAIN, WALEED A., ET AL. "AN ELECTROCHEMICAL BIOSENSOR FOR THE RAPID DETECTION OF ERYTHROPOIETIN IN BLOOD." TALANTA, VOL. 189, NOV. 2018, PP. 636-40. DOI.ORG (CROSSREF), DOI:10.1016/J.TALANTA.2018.07.045.

HOU, SIYUAN, ET AL. "A SIMPLE, FAST, AND ACCURATE THERMODYNAMIC-BASED APPROACH FOR TRANSFER AND PREDICTION OF GAS CHROMATOGRAPHY RETENTION TIMES BETWEEN COLUMNS AND INSTRUMENTS PART I: ESTIMATION OF REFERENCE COLUMN GEOMETRY AND THERMODYNAMIC PARAMETERS." JOURNAL OF SEPARATION SCIENCE, VOL. 41, NO. 12, JUNE 2018, PP. 2544–52. DOI.ORG (CROSSREF), DOI:10.1002/JSSC.201701343.

LOBIGS, LOUISA M., ET AL. "VALIDATION OF A BLOOD MARKER FOR PLASMA VOLUME IN ENDURANCE ATHLETES DURING A LIVE-HIGH TRAIN-LOW ALTITUDE TRAINING CAMP." DRUG TESTING AND ANALYSIS, VOL. 10, NO. 7, JULY 2018, PP. 1176-83. DOI.ORG (CROSSREF), DOI:10.1002/DTA.2370.

MONCRIEFFE, DANIELLE, ET AL. "PEPTIDE SELECTION FOR THE QUANTIFICATION OF P-III-NP IN HUMAN SERUM BY MASS SPECTROMETRY." RAPID COMMUNICATIONS IN MASS SPECTROMETRY, VOL. 32, NO. 7, APR. 2018, PP. 535-42. DOI.ORG (CROSSREF), DOI:10.1002/RCM.8066.

POLET, MICHAEL, ET AL. "DEVELOPMENT AND VALIDATION OF AN OPEN SCREENING METHOD FOR DOPING SUBSTANCES IN URINE BY GAS CHROMATOGRAPHY QUADRUPOLE TIME-OF-FLIGHT MASS SPECTROMETRY." ANALYTICA CHIMICA ACTA, VOL. 1042, DEC. 2018, PP. 52-59. DOI.ORG (CROSSREF), DOI:10.1016/J.ACA.2018.08.050.

SAVKOVIC, SASHA, ET AL. "URINE AND SERUM SEX STEROID PROFILE IN TESTOSTERONE-TREATED TRANSGENDER AND HYPOGONADAL AND HEALTHY CONTROL MEN." THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, VOL. 103, NO. 6, JUNE 2018, PP. 2277-83. DOI.ORG (CROSSREF), DOI:10.1210/JC.2018-00054.

TOBIAS, HERBERT J., AND J. THOMAS BRENNA. "CRYOFOCUS FAST GAS CHROMATOGRAPHY COMBUSTION ISOTOPE RATIO MASS SPECTROMETRY FOR RAPID DETECTION OF SYNTHETIC STEROID USE IN SPORT DOPING." THE ANALYST, VOL. 143, NO. 5, 2018, PP. 1124-32. DOI.ORG (CROSSREF), DOI:10.1039/C7AN01398A.

TOBIAS, HERBERT J., AND J. THOMAS BRENNA.. "HIGH-VOLUME STEROID ISOTOPIC STANDARDS DEVELOPED AS WORKING STANDARDS FOR GAS CHROMATOGRAPHY-COMBUSTION-ISOTOPE RATIO MASS SPECTROMETRY." DRUG TESTING AND ANALYSIS, VOL. 10, NO. 4, APR. 2018, PP. 781-85. DOI.ORG (CROSSREF), DOI:10.1002/DTA.2309.

YANG, WEN-HSUAN, ET AL. "ANGIOGENIN-MEDIATED TRNA CLEAVAGE AS A NOVEL FEATURE OF STORED RED BLOOD CELLS." BRITISH JOURNAL OF HAEMATOLOGY, VOL. 185, NO. 4, MAY 2019, PP. 760-64. DOI.ORG (CROSSREF), DOI:10.1111/BJH.15605.

Presentations

D. COWAN, C. BARTLETT, D. BÖHNING, W. BÖHNING, N. GUHA, RIG. HOLT, PH. SÖNKSEN, N. WOJEK, JO. BECKER, LD. BOWERS, AW. BUTCH, H. COX, A. HOOFNAGLE, F. LOPES, M. PARKIN, M. THEVIS, A. THOMAS, G. WOLDEMARIAM : IGF-1 AND P-III-NP BIOMARKERS OF HUMAN GROWTH HORMONE ADMINISTRATION - THREE ADDITIONAL METHODS FOR MEASUREMENT AND DETERMINATION OF THE BIOMARKER SCORE. 36TH COLOGNE WORKSHOP ON DOPE ANALYSIS. APRIL 2018. COLOGNE, GERMANY.

D. MONCRIEFFE, D. COWAN, M. PARKIN: PEPTIDE SELECTION FOR THE QUANTIFICATION OF P-III-NP IN HUMAN SERUM BY MASS SPECTROMETRY. 36TH COLOGNE WORKSHOP ON DOPE ANALYSIS. APRIL 2018. COLOGNE, GERMANY.

E. OLESTI, D. FABREGAT-SAFONT, M. IBAÑEZ, JV. SANCHO, F. HERNÁNDEZ, R. DE LA TORRE, AND O. POZO. FACING THE PROBLEM OF NEW PSYCHOACTIVE SUBSTANCES FOR DOPING CONTROL ANALYSIS. TIAFT 2018. GHENT, BELGIUM.

E. OZGUR, K. ROBERTS, A. GIN, J. BANKHEAD, & TJ. SU. RAPID, LABEL-FREE, AND ULTRA-SENSITIVE DETECTION OF URINE HCG USING FREQUENCY-LOCKED ON-CHIP OPTICAL MICROCAVITIES. BMES 2018. ATLANTA, USA.

G. MILLER, D. EICHNER, S. WILLICK, B. HILL, V. NAIR, C MOORE: CLOMIPHENE ADMINISTRATION TO MALES RESULTS IN A TESTOSTERONE INCREASE AND IS ACCOMPANIED BY A LENGTHY, ISOMER-SPECIFIC DETECTION WINDOW IN URINE. 36TH COLOGNE WORKSHOP ON DOPE ANALYSIS. APRIL 2018. COLOGNE, GERMANY

H. COX, G. MILLER, A. LAI, D. EICHNER: IMPROVED DETECTION OF BLOOD DOPING PRACTICES USING A DRIED BLOOD SPOT METHOD TO MEASURE IMMATURE RETICULOCYTES. 36TH COLOGNE WORKSHOP ON DOPE ANALYSIS. APRIL 2018. COLOGNE, GERMANY.

H. TOBIAS AND J. BRENNA. LOW TEMPERATURE CATALYTIC COMBUSTION REACTOR FOR GAS CHROMATOGRAPHY ISOTOPE RATIO MASS SPECTROMETRY. 65TH ASMS CONFERENCE ON MASS SPECTROMETRY AND ALLIED TOPICS. JUNE 2018. SAN DIEGO, USA.

J. HENION, R. VERPLAETSE, AND I. RYONA. DO MICRO SAMPLING TECHNIQUES HAVE A PLACE IN THE FORENSIC LABORATORY? LC/MS AND NON-LC/MS APPLICATIONS. TIAFT 2018. GHENT, BELGIUM.

J. NAUD, P. DESHARNAIS, AND C. AYOTTE. DEVELOPMENT OF A CAPILLARY-ELECTROPHORESIS METHOD FOR THE DETECTION OF RECOMBINANT ERYTHROPOIETINS. 36TH COLOGNE WORKSHOP ON DOPE ANALYSIS. APRIL 2018. COLOGNE, GERMANY.

J. SU. THE LITTLE SENSOR LAB. NSF NANOSCALE SCIENCE AND ENGINEERING GRANTEES CONFERENCE. DECEMBER 2018. VIRGINIA, USA.

M. FEDORUK. DRIED BLOOD SPOT (DBS) TESTING & THE POTENTIAL FOR THE ABP. WADA ABP SYMPOSIUM. NOVEMBER 2018. ROME, ITALY.

M. POLET, W. VAN GANSBEKE, AND P. VAN EENOO. GC-QTOF-MS: TOWARDS A COMPLETE AND OPEN SCREENING METHOD. 36TH COLOGNE WORKSHOP ON DOPE ANALYSIS. APRIL 2018. COLOGNE, GERMANY

M. POLET, W. VAN GANSBEKE, AND P. VAN EENOO. TARGETED AND UNTARGETED SCREENING METHODS BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY FOR DOPING, FORENSIC AND TOXICOLOGICAL PURPOSES. TIAFT 2018. GHENT, BELGIUM.

M. POLET, W. VAN GANSBEKE, AND P. VAN EENOO. TARGETED AND UNTARGETED SCREENING METHODS BY GAS CHROMATOGRAPHY MASS SPECTROMETRY FOR DOPING, FORENSIC AND TOXICOLOGICAL. AGILENT WEBINAR.

M. POLET, W. VAN GANSBEKE, AND P. VAN EENOO. THE POWER OF GC/Q-TOF AND GC/QQQ FOR ANTI-DOPING AGENTS. AGILENT DAY BELUX. JUNE 2018. GHENT, BELGIUM.

O. KRUG, A. THOMAS, H. GEYER, AND M. THEVIS. TESTING DOPING AGENTS FROM EXHALED BREATH - PILOT STUDY DATA. 36TH COLOGNE WORKSHOP ON DOPE ANALYSIS. APRIL 2018. COLOGNE, GERMANY P. VAN EENOO, M. POLET, W. VAN GANSBEKE, R. VAN LOON, K. BRADY. GC/Q-TOF TECHNICAL INNOVATIONS ALLOW TRACE ANALYSIS AND SCREENING OF DRUG RELATED SUBSTANCES. 42ND INTERNATIONAL SYMPOSIUM ON CAPILLARY CHROMATOGRAPHY AND 15TH GCXGC SYMPOSIUM. MAY 2018. RIVA DEL GARDA, ITALY.

S. NIETO, W. VAN GANSBEKE, M. POLET, B. WUEST, N. ENO, P. VAN EENOO. ANALYSIS OF DOPING AND FORENSIC DRUGS IN URINE USING HIGH-RESOLUTION GC/Q-TOF. 66TH ASMS CONFERENCE ON MASS SPECTROMETRY AND ALLIED TOPICS. JUNE 2018. SAN DIEGO, USA.

V. NAIR, G. MILLER, S. MORRISON, M. SUMMERS, S. WILLICK, D. EICHNER: INTRANASAL DELIVERY OF NATESTO TESTOSTERONE GEL AND ITS EFFECT ON DOPING MARKERS. 36TH COLOGNE WORKSHOP ON DOPE ANALYSIS. APRIL 2018. COLOGNE, GERMANY.

BY THE NUMBERS



FINANCIALS

\$3,500,000 \$3,000,000 \$2,500,000 \$2,000,000

\$1,500,000

an operational contractions

Financial Statements and Report of Independent Certified Public Accountants

Partnership for Clean Competition Research Collaborative

December 31, 2018 and 2017

Contents

_			
Р	а	a	e

Report of Independent Certified Public Accountants	2
Statements of financial position	4
Statements of activities	5
Statements of cash flows	6
Notes to financial statements	7



GRANT THORNTON LLP

515 S. Flower St., 7th Floor Los Angeles, CA 90071-2201

D +1 213 627 1717

F +1 213 624 6793

S linkd.in/grantthorntonus twitter.com/grantthorntonus

Report of Independent Certified Public Accountants

The Board of Governors of the Partnership for Clean Competition Research Collaborative

We have audited the accompanying financial statements of the Partnership for Clean Competition Research Collaborative ("PCC"), which comprise the statements of financial position as of December 31, 2018 and 2017, and the related statements of activities and changes in net assets and cash flows for the years then ended, and the related notes to the financial statements.

Management's responsibility for the financial statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.



We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Partnership for Clean Competition Research Collaborative as of December 31, 2018 and 2017, and the changes in their net assets and their cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Sant Thornton LLP

Los Angeles, California October 15, 2019

Statements of financial position

	As of December 31,					
		2018			2017	
Assets						
Cash and cash equivalents	\$	4,882,853		\$	5,223,133	
Restricted cash		1,739,612			1,739,612	
Pledges receivable, net		1,252,268			367,034	
Prepaid expenses		7,076			7,261	
Prepaid fellowship		181,250			-	
Software, net		58,229			102,834	
Total assets	\$	8,121,288		\$	7,439,874	
			1			
Liabilities and net assets						
Liabilities						
Accounts payable and accrued liabilities	\$	542,430		\$	47,702	
Total liabilities		542,430			47,702	
Net assets						
Without donor restrictions		5,242,273			6,520,821	
With donor restrictions		2,336,585			871,351	
Total net assets		7,578,858			7,392,172	
Total liabilities and net assets	\$	8,121,288		\$	7,439,874	

Statements of activities

	Yea	r ended December 31,	2018	Year ended December 31, 2017				
	Net assets without donor restrictions	Net assets with donor restrictions	Total	Net assets without donor restrictions	Net assets with donor restrictions	Total		
Support and revenue								
Contributions	\$ 2,315,955	\$ 580,000	\$ 2,895,955	\$ 2,500,000	\$-	\$ 2,500,000		
Other	89,116	-	89,116	30,559	-	30,559		
Net assets released from restrictions	(885,234)	885,234	-	370,683	(370,683)	-		
Total support and revenue	1,519,837	1,465,234	2,985,071	2,901,242	(370,683)	2,530,559		
Expenses								
Program services:								
Anti-doping research	2,422,962	-	2,422,962	1,993,425	-	1,993,425		
Total program services	2,422,962	-	2,422,962	1,993,425	-	1,993,425		
Supporting services								
Fundraising	33,797	-	33,797	28,462	-	28,462		
General and administrative	341,626	-	341,626	353,634	-	353,634		
Total supporting services	375,423	-	375,423	382,096	-	382,096		
Total expenses	2,798,385	-	2,798,385	2,375,521	-	2,375,521		
Changes in net assets	(1,278,548)	1,465,234	186,686	525,721	(370,683)	155,038		
Net assets, beginning of period	6,520,821	871,351	7,392,172	5,995,100	1,242,034	7,237,134		
Net assets, end of period	\$ 5,242,273	\$ 2,336,585	\$ 7,578,858	\$ 6,520,821	\$ 871,351	\$ 7,392,172		

The accompanying notes are an integral part of these financial statements.

Statements of cash flows

	Years ended December 31			
	2018	2017		
Operating activities				
Change in net assets	\$ 186,686	\$ 155,038		
Adjustments to reconcile changes in net assets to net cash (used in) (used in) provided by operating activities				
Amortization	44,605	44,065		
Changes in assets and liabilities				
(Increase) decrease in pledges receivable, net	(885,234)	375,000		
(Increase) decrease in prepaid expenses and prepaid fellowship	(181,065)	80,230		
Increase (decrease) in accounts payable and accrued liabilities	494,728	(69,567)		
(Decrease) increase in grants payable		(104,131)		
Net cash (used in) provided by operating activities	(340,280)	480,635		
Investing activities				
Change in restricted cash	-	20,366		
Purchase of software		(8,813)		
Net cash provided by (used in) investing activities		11,553		
Net (decrease) increase in cash and cash equivalents	(340,280)	492,188		
Cash and cash equivalents, beginning of year	5,223,133	4,730,945		
Cash and cash equivalents, end of year	\$ 4,882,853	\$ 5,223,133		

Notes to financial statements

Note A – Summary of significant accounting policies

Organization

The Partnership for Clean Competition Research Collaborative ("PCC") was established on February 21, 2008 as a not-for-profit organization established under IRC Section 501(c)(3) with the United States Olympic Committee ("USOC") as the sole IRC Section 501(c)(3) member. PCC's mission is to protect the integrity of sport and public health by engaging and supporting the world's top scientists and innovators in high-quality anti-doping research and development. By combining the resources and expertise of America's leading sports entities, the PCC supports non-partisan and independent scientific research by fundraising and making targeted grants to various universities and other world-class research institutions. This independent research primarily focuses on developing more effective tests for performance-enhancing substances and non-test based methods to decrease doping and performance-enhancing drug use across all levels of athletic participation and competition, from the casual youth sports participant to the elite amateur and professional athlete. The PCC also facilitates adoption of these methods into the World Anti-Doping Agency accredited laboratories.

The PCC is governed under the direction of a Board of Governors consisting of three constituent classes of members: one class of members is comprised of USOC representatives; one class of members is comprised of representatives from professional sports leagues, unions of professional athletes and/or other individuals that make demonstrated, long-term economic commitments in support of the PCC; the final class of members is comprised of a representative from the United States Anti-Doping Agency.

The PCC board is supported by a Scientific Research Advisory Board, who independently reviews the relative merits of particular research projects and makes recommendations to the Board of Governors as to appropriate areas and subjects for making scientific research grants. This advisory body is comprised of members who are universally-recognized experts in their field or scientific expertise, individuals from academia, individuals from the public health sector and/or individuals who otherwise represent the public interest.

The Executive Director of the PCC oversees the day-to-day administration of the organization and reports directly to the Board of Governors.

December 31, 2018 and 2017

Note A – Summary of significant accounting policies (continued)

Basis of presentation

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles general accepted in the United States of America.

Net assets

In accordance with Financial Accounting Standards Board ("FASB") Accounting Standard Update ("ASU") No. 2016-14, *Not-for-Profit Entities (Topic 958)*, PCC classifies its financial position and activities into two classes of net assets: net assets without donor restrictions and net assets with donor restrictions. Accordingly, net assets of the PCC and changes therein are classified and reported as follows:

- Net assets without donor restrictions Net assets that are not subject to donor-imposed stipulations and are available for use in general operations. Any Board designated funds are also included within net assets without donor restrictions. As of December 31, 2018 and December 31, 2017, there were no Board designated funds.
- Net assets with donor restrictions Net assets that are subject to donor-imposed stipulations that may or will be met either with actions of the PCC and/or the passage of time or other events specified by the donor. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as net assets released from restrictions. Other donor-imposed restrictions could be perpetual in nature, however as of December 31, 2018 and December 31, 2017, there were no such funds.

Contributions

Contributions represent unconditional cash donations and future pledges of cash donations from the organizations represented on the Board of Governors, as well as donations from the general public. The PCC reports contributions of cash and other assets as net assets with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or the donor stipulations have been met, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported as net assets released from restrictions in the statements of activities. Contributions of cash and other assets that are originally restricted by the donor and for which the restriction is met in the same time period are recorded as net assets without donor restrictions.

Unconditional promises to give (pledges) to the PCC in the future or over a period spanning multiple years are recorded as net assets with donor restrictions at the estimated fair value when the pledge is made. Fair value is determined by computing the present value of future cash flows discounted at the risk-free interest rate as of the period in which the agreement was received, adjusted for any associated credit risks. As cash donations are received under the pledge, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported as net assets released from restrictions in the statements of activities.

December 31, 2018 and 2017

Note A – Summary of significant accounting policies (continued)

Cash and cash equivalents

Cash and short term investments with original maturities of three months or less from the date of acquisition are considered cash and cash equivalents. As of December 31, 2018 and 2017, all cash and cash equivalents represent demand deposits.

Restricted cash

Restricted cash of \$1,739,612 as of December 31, 2018 and 2017, consists of cash held in custody of the World Anti-Doping Agency (WADA) that is restricted for funding PCC anti-doping research grants in partnership with WADA.

Pledges receivable

Pledges receivable, net of an annual discount of 1.41%, are deemed fully collectible as of December 31, 2018 and 2017. Pledges are due to be collected over the coming years in the following amounts:

	As o	f December 31, 2018
Year ending December 31, 2019 2020	\$	1,128,985 123,283
	\$	1,252,268

For the years ended December 31, 2018 and 2017, \$3,901 and \$5,596, respectively, of the pledge discount was amortized into contribution revenue. As of December, 31, 2018 and 2017, the unamortized pledge discount was \$2,622 and \$6,253, respectively.

Recent accounts pronouncements

In August 2016, the FASB issued ASU 2016-14, *Not-for-Profit Entities (Topic 958)*. The provisions of this ASU include a change from three classes of net assets to two; net assets with donor restrictions and net assets without donor restrictions. Certain enhanced disclosures are also required. PCC has adopted this ASU beginning with the year ended December 31, 2018 and applied the changes to the amounts previously reported for the year ended December 31, 2017.

The changes resulting from the adoption of this ASU can be seen on the financial statements and in a number of the footnotes. The adoption of this ASU did not change any amounts previously reported for the year ended December 31, 2017.

December 31, 2018 and 2017

Note A – Summary of significant accounting policies (continued)

Recent accounts pronouncements (continued)

In May 2014, the FASB issued ASU No. 2014-09, *Revenue from Contracts and Customers (Topic 606)*. This standard will eliminate the transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. The provisions of this ASU will include requiring accounting for the liability for each benefit provided to a donor as part of a contribution received for a membership or for an event sponsorship. The provisions in this ASU are effective for fiscal years beginning after December 15, 2018 (i.e., applicable for the year ending December 31, 2019 for PCC). PCC is currently evaluating the impact of adopting this ASU.

In February 2016, the FASB issued ASU No. 2016-02, *Leases (Topic 842)*. Lessees will need to recognize nearly all lease transactions (other than leases that meet the definition of a short-term lease) on the statement of financial position as a lease liability and a right-of-use asset (as defined). The provisions in this ASU are effective for fiscal years beginning after December 15, 2019 (i.e., applicable for the year ending December 31, 2020 for PCC). PCC is currently evaluating the impact of adopting this ASU.

Software

Costs of computer software developed or obtained for internal use are recorded in accordance with Accounting Standards Codification (ASC) Topic 350. Under Topic 350, costs incurred during the preliminary project stage are expensed as incurred, costs incurred during the application development stage are capitalized and training and maintenance costs incurred during the post-implementation / operation stage are expensed as incurred. Amortization of software is provided on the straight-line method over an estimate useful life of 5 years.

Software is reported net of accumulated amortization of \$160,152 and \$115,548 as of December 31, 2018 and 2017, respectively.

Grants payable

The PCC awards targeted grants to research institutions each year in order to fund independent scientific research projects aimed at increasing detection and prevention of performance-enhancing substance use in professional and amateur sports. The research projects generally extend over a period of one to three years. The liability is recorded as grants payable in the statements of financial position and the associated expense is recorded as anti-doping research expense in the statements of activities when the grant agreements are executed by the PCC.

Federal income taxes

The PCC is exempt from federal and state income taxes on income from activities related to its exempt purposes under IRC Section 501(a) of the Internal Revenue Code as an organization described in IRC Section 501(c)(3). The PCC had no unrelated business income for the periods ended December 31, 2018 and 2017.

December 31, 2018 and 2017

Note A – Summary of significant accounting policies (continued)

Functional expenses

The cost of providing supporting services has been summarized on a functional basis in the statements of activities. Certain costs have been allocated among the supporting services benefited based on labor dollars, costs incurred or another methodology considered reasonable by management.

Management estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions. Such estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates.

Uncertain tax positions

As required by the uncertain tax position guidance, the PCC recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-thannot threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The adoption of this guidance did not have a material effect on PCC's financial statements.

Note B – Service agreement

The PCC has a service agreement with the USOC where the USOC has agreed to make available to the PCC various services including the payroll, legal services, communications and public relations, information technology and human resources. The PCC is obligated to reimburse the USOC for these services, which have been calculated at the USOC's cost. For employee costs, the PCC is billed for actual labor, benefits and payroll tax costs incurred. Legal and accounting services are billed to the PCC at a fixed monthly rate. Information technology, human resources and communication services are reimbursed to the USOC based on an hourly rate for services performed. For the years ended December 31, 2018 and 2017, the amount PCC incurred from the USOC for these services was \$322,834 and \$298,605, respectively.

Note C – Functional expenses

Expenses are recorded in the general ledger by both function and nature. The statements of activities present expenses by function with certain expenses (e.g., depreciation) allocated across functional categories. Expenses allocated by both function and nature, for the years ended December 31, 2018 and 2017, respectively, are as follows:

For the year ended December 31, 2018

				Supp	port S	Servic	es				
	Program Services		Fundraising			General and Administration		Total Support Services		2	018 Total
Direct program expenses	\$	2,113,057	\$	24,147		\$	178,172	\$	202,319	\$	2,315,376
Fellowships and consultants		169,781		-			-		-		169,781
Conferences		52,596		-			-		-		52,596
Benefits		-		7,999			71,997		79,996		79,996
Travel		10,957		-			18,776		18,776		29,733
Supplies and office expenses		-		-			7,411		7,411		7,411
Depreciation		43,267		1,338			-		1,338		44,605
Website expenses		10,106		313			-		313		10,419
Insurance		-		-			18,213		18,213		18,213
Advertising		23,198		-			-		-		23,198
Professional services and dues		-		-			47,057		47,057		47,057
Total	\$	2,422,962	\$	33,797		\$	341,626	\$	375,423	\$	2,798,385

For the year ended December 31, 2017

,	,			Support Services						
	Program			General and		Tot	Total Support			
		Services	Fu	ndraising	Adr	ninistration		Services	2	017 Total
Direct program expenses	\$	1,749,318	\$	18,106	\$	174,775	\$	192,881	\$	1,942,199
Fellowships and consultants		92,193		-		-		-		92,193
Conferences		69,194		-		-		-		69,194
Benefits		-		8,946		80,518		89,464		89,464
Travel		26,527		-		19,054		19,054		45,581
Supplies and office expenses		-		-		32,170		32,170		32,170
Depreciation		42,743		1,322		-		1,322		44,065
Website expenses		2,808		88		-		88		2,896
Insurance		-		-		18,433		18,433		18,433
Advertising		10,642		-		-		-		10,642
Professional services and dues		-		-		28,684		28,684		28,684
Total	\$	1,993,425	\$	28,462	\$	353,634	\$	382,096	\$	2,375,521

December 31, 2018 and 2017

Note D – Liquidity

The following table reflects the PCC's financial assets as of December 31, reduced by amounts not available for general expenditure within one year. Financial assets are considered unavailable when illiquid or not convertible to cash within one year, perpetual endowments and accumulated earnings net of appropriations within one year, or because the governing board has set aside the funds for a specific contingency reserve or a long-term investment as board designated endowments. Board designated assets could be drawn upon with board approval.

	2018		 2017		
Financial assets:					
Cash and cash equivalents	\$	4,882,853	\$ 5,223,133		
Restricted cash		1,739,612	1,739,612		
Pledges receivable, net		1,252,268	367,034		
Total financial assets		7,874,733	7,329,779		
Less those unavailable for general expenditures within one year:					
Restricted cash		(1,739,612)	(1,739,612)		
Pledges to be collected beyond one year		(123,283)	(248,974)		
Financial assets available to meet cash needs for general expenditures within					
one year	\$	6,011,838	\$ 5,341,193		

The PCC's practice is to structure its financial assets to be available as its general expense, liabilities and obligations come due. The PCC's goal is to operate with a balanced budget and anticipates collecting sufficient revenue to cover operational expenditures. Excess operational cash is invested until needed.

Note E – Subsequent events

The PCC has evaluated subsequent events through the date that the financial statements were available to be issued on October 15, 2019. Management was not aware of any subsequent events which would require recognition or disclosure in the financial statements.